(A) Serum levels of ghrelin in AL and DR wild-type mice (left) and in fed and fasted BRASTO (Tg) and control (WT) mice (right). Ghrelin levels are shown as mean values ± SEM (**P<0.01, ***P<0.001 by one-way ANOVA with Tukey-Kramer post hoc test, n=5 for each condition). (B) The number of cFOS-positive cells in the Arc, DMH, and LH of wild-type (WT) and BRASTO (Tg) mice at 90 min (left) and 120 min (right) after ghrelin injection (30 nmol/kg of body weight) and after PBS injection (right). cFOS-positive cells are shown as mean values ± SEM (*P<0.05, **P<0.01 by one-way ANOVA with Tukey-Kramer post hoc test for each hypothalamic nucleus, ghrelin injection, 90 min, n=2-3 mice for each genotype, 7-12 sections per hypothalamic nucleus; 120 min, n=3 for each genotype, 3-7 sections per hypothalamic nucleus, PBS injection, n=2 for each genotype, 6-7 sections per hypothalamic nucleus). (C) Rectal body temperature of BRASTO mice 120 min after ghrelin injection. Levels of rectal body temperature are shown as mean values ± SEM (*P<0.05, **P<0.01 by one-way ANOVA with Tukey-Kramer post hoc test, n=6-7). (D) Double immunofluorescent staining of cFOS and OX2R in the DMH and LH of wild-type (WT) and BRASTO (Tg) mice at 120-min after ghrelin injection. Arrows indicate cFOS/OX2R-double positive cells. (E) Quantification of the number of cFOS/OX2R-double positive cells in the Arc, DMH and LH of wild-type (WT) and BRASTO (Tg) mice at 120 min after ghrelin injection. cFOS/OX2R-double positive cells are shown as mean values ± SEM (*P<0.05, n=3 mice for each genotype, 3-7 sections per hypothalamic nucleus). (F) Percent of cFOS/OX2R-double positive cells compared to a total number of cFOS-positive cells in the Arc, DMH, and LH of Sirt1+/+ and Sirt1-/- mice at 120 min after ghrelin injection. Percent of cFOS/OX2R-double positive cells are shown as mean values ± SEM (*P<0.05, ***P<0.001, n=3 mice for each genotype, 6-12 sections per hypothalamic nucleus). (G) A model for the SIRT1-mediated neurobehavioral adaptation in the hypothalamus in response to DR. See Discussion for details.